In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

regulator of phosphorus-calcium metabolism, which is used for systemic osteoporosis. the drug has a double effect on bone metabolism: stimulating - on osteoblasts, and inhibitory - on osteoclasts. these various actions are physiologically complementary and regulate the balance between bone resorption and bone restoration.

Calcium, which is part of the drug, is contained in the form of hydroxyapatite, which contributes to a more complete absorption of calcium in the digestive tract. In addition, it inhibits the synthesis of parathyroid hormone and prevents hormone-mediated bone resorption. Slow release of calcium from hydroxyapatite causes the absence of a peak in hypercalcemia. Phosphorus, which is involved in the crystallization of hydroxyapatite, promotes the fixation of calcium in the bones and inhibits its excretion by the kidneys. The organic component of the drug (ossein) contains local bone remodeling regulators (transforming growth factor-beta (β-TGF), insulin-like growth factors I, II (IGF-I, IGF-II), osteocalcin, type I collagen, which activate the process of bone formation β-TGF stimulates the activity of preosteoblasts, increases their number, promotes collagen formation, and inhibits the formation of osteoclast precursors. IGF-I and IGF II stimulate collagen synthesis. Osteocalcin promotes bone crystallization by Calcium binding: Type I collagen provides bone matrix formation.

Pharmacokinetics Absorption occurs at the level of the duodenum and proximal small intestine.


Primary osteoporosis: pre- and postmenopausal, menopause, senile.

Secondary osteoporosis: due to the use of corticosteroids and / or heparin, immobilization, rheumatoid arthritis, liver and kidney diseases, hyperthyroidism, hyperparathyroidism, imperfect osteogenesis.

Treatment of disorders of phosphorus-calcium metabolism during pregnancy and lactation.

To accelerate the consolidation of bone fractures.

With dysplasia of the joints and connective tissue.

As part of a comprehensive treatment for scoliosis, rickets of the skeleton.


Inside, washed down with a small amount of water.

With systemic osteoporosis, adults are prescribed 2–4 tablets 2 times a day. To accelerate the consolidation of bone fractures - 2 tablets 2-3 times a day. With other indications - 1-2 tablets per day. The duration of treatment for osteoporosis is 6-12 months; with bone fractures, after joint replacement and all other indications - 3 months. The duration of therapy is determined by the doctor depending on the degree of bone marrow maturity.


Hypersensitivity to the drug, hypercalcemia, severe hypercalciuria, severe renal impairment, childhood.

Side effects

Osteogenon is well tolerated. persons with hypersensitivity may develop allergic reactions, with prolonged use - hypercalcemia, hypercalciuria.

special instructions

Osteogenon contains a small amount of sodium chloride, so the drug can be used for a long time in patients with ag.

In patients with impaired renal function, a high dose of the drug should not be used for a long time.

In patients with a tendency to develop urolithiasis, it is necessary to adjust the dose depending on the condition.

During pregnancy and breastfeeding. No adverse effects on the fetus and child were detected.

Children. Do not use in children under the age of 18 years.

The ability to influence the management of vehicles and work with complex mechanisms. The drug does not affect the ability to drive vehicles and work with mechanisms.


Due to the formation of chelates, it slows down the absorption of iron preparations and tetracycline antibiotics, so it is recommended to take osteogenone no earlier than 4 hours after taking these drugs.

With the simultaneous use of Osteogenon with vitamin D or thiazide diuretics, it is necessary to assess the degree of hypercalcemia due to increased calcium resorption.


When using the drug in therapeutic doses, there is no risk of overdose. with an overdose, an increase in the severity of side effects is possible.

Storage conditions

At a temperature not exceeding 25 ° C.

Tags: Osteogenon